{"id":"NCT02786901","sponsor":"Bausch & Lomb Incorporated","briefTitle":"LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","officialTitle":"A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2017-06-13","completion":"2017-07-01","firstPosted":"2016-06-01","resultsPosted":"2020-04-14","lastUpdate":"2021-01-08"},"enrollment":600,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cataract","Pain","Ocular Inflammation"],"interventions":[{"type":"DRUG","name":"Loteprednol Etabonate Ophthalmic Gel dosed TID","otherNames":["LE"]},{"type":"DRUG","name":"Loteprednol Etabonate Ophthalmic Gel dosed BID","otherNames":["LE"]},{"type":"DRUG","name":"Vehicle Gel","otherNames":["Vehicle"]}],"arms":[{"label":"Loteprednol Etabonate Ophthalmic Gel dosed TID","type":"EXPERIMENTAL"},{"label":"Loteprednol Etabonate Ophthalmic Gel dosed BID","type":"EXPERIMENTAL"},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR"}],"summary":"Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.","primaryOutcome":{"measure":"Number of Participants With Complete Resolution of Anterior Chamber (AC) Cells at Visit 5 (Postoperative Day 8)","timeFrame":"8 days","effectByArm":[{"arm":"Vehicle BID and TID","deltaMin":40,"sd":null},{"arm":"LE Gel BID","deltaMin":52,"sd":null},{"arm":"LE Gel TID","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":198},"commonTop":[]}}